DENVER, June 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) – NeOnc Technologies Holdings (NASDAQ: NTHI ) continues to build momentum as a neuro-oncology sector trailblazer, as it advances multiple clinical programs targeting some of the most difficult cancers to treat, after announcing that the Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for NEO212, the company's oral perillyl alcohol-temozolomide conjugate being developed for aggressive brain tumors. The approval represents the first international regulatory clearance for NEO212 following completion of the Phase 1 dose-escalation study, which established 610 mg as the recommended Phase 2 dose. The authorization creates an additional clinical development pathway outside the United States as the company continues discussions with the U.S. Food and Drug Administration regarding a potential registrational strategy. The company is focused on developing therapies for glioblastoma and other aggressive central nervous system cancers while addressing one of the industry's most persistent challenges: the blood-brain barrier. For decades, many promising oncology therapies have struggled to achieve meaningful clinical success in brain cancers because drug molecules often fail to penetrate the brain in sufficient concentrations. NeOnc's platform is designed to overcome this obstacle through innovative delivery technologies intended to improve therapeutic access to tumor tissue while potentially reducing systemic toxicity. NEO100 Advances Toward Key Data Readout One of the company's most closely watched programs is NEO100, a patented intranasal composition of a proprietary synthesis perillyl alcohol designed for direct nose-to-brain delivery. The program has now achieved full enrollment in its Phase 2a study evaluating recurrent IDH1-mutant high-grade glioma and related brain cancers. Recent updates have highlighted encouraging clinical observations, including tumor remission reported in approximately 24% of recurrent glioblastoma patients treated with NEO100. Investors are now looking toward anticipated interim and top-line data expected later in 2026, which many view as potentially significant value-inflection events for the company. Analysts have identified NEO100 as one of NeOnc's primary near-term catalysts, citing the program's differentiated delivery approach and the ... Full story available on Benzinga.com
Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND
